Selective CDK2 inhibitor developer advancing INX-315 for CDK4/6-resistant ER+/HER2- breast cancer and CCNE1-amplified solid tumors.
At a glance
- HQ: RTP
- Sector: Biotech
- Stage: Series B
- Total raised: $47M
- Last round: Series B
This is the free preview.
The full profile is for members: founders, funding history, investor connections, and recent signals. Accounts are free; I review every request, usually within 48 hours.